Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2023 Earnings Call Transcript

So the script will be sent into the electronic medical system. Questions may be asked back to confirm it’s PPD. And that script, our goals and days should arrive in the hands of the postpartum women and ready to treat. And hopefully, each and every woman sees the kind of result it’s on clinical practice, so a rapid improvement in clinical development, a rapid improvement in depressive systems as early as 3 days, complete your 14-day impacting. We have goals to reengage with baby and family. So we really do believe that ZURZUVAE in PPD works like other prescriptions out there, scripts written, those suffering receive that drug very, very rapidly. And all of those lessons have been applied to the commercialization of ZURZUVAE.

Operator: We now turn to Barry Greene for any additional or closing remarks.

Barry Greene: Thanks, Melinda, and thanks again to everyone for joining us this morning to review our results from the third quarter of 2023. As we look ahead to the commercial availability and subsequent launch of ZURZUVAE in the treatment of women with PPD and prepare to enter what we believe will be a catalyst-rich 2024 with multiple data readouts expected that provide the potential for long-term value creation, I’m confident that we’re making important progress to deliver our mission to develop and launch life-changing brain health medicines so every person can thrive. Thanks again, everyone. Have a great day.

Operator: Thank you. This does conclude today’s teleconference. We thank you for your participation. You may disconnect your lines at any time.